Original Source(s)
Related Content
FDA expands talazoparib use in prostate cancer
The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .
by Mouj Hijazi
October 27, 2026
-
3 min
FDA raises TMB threshold for pembrolizumab
Traditional approval narrows eligibility for previously treated solid tumors after efficacy was not confirmed at lower biomarker levels.
by Mouj Hijazi
October 23, 2026
-
3 min
FDA clears at-home risankizumab induction
Week 12 remission reached 56% vs. 30% with placebo, with the FDA revising tuberculosis testing precautions.
by Teraya Smith
October 23, 2026
-
2 min